Clinical trial · Observational
Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening
Parallel Controlled Study of Epstein-Barr Virus Antibody and Epstein-Barr Virus DNA for Nasopharyngeal Carcinoma Screening in the High-risk Population
NCT05447169CI-TRIAL-00059554recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The investigators intend to compare Epstein-Barr virus antibody and Epstein-Barr virus DNA screening efficacy in first-degree relatives of nasopharyngeal carcinoma patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| EBV antibodies test | Diagnostic Test | — | UNRESOLVED |
| EBV DNA test | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- High risk population of nasopharyngeal carcinoma
- description
- first-degree relatives of nasopharyngeal carcinoma patients, aged 30-62 male
- interventionNames
- Diagnostic Test: EBV antibodies test
- Diagnostic Test: EBV DNA test
Primary outcomes (2)
- measure
- positive predictive value
- timeFrame
- 3 years
- description
- the ratio of subjects truly diagnosed as nasopharyngeal carcinoma to all those who had positive test results
- measure
- negative predictive value
- timeFrame
- 3 years
- description
- the ratio of subjects truly diagnosed as negative (do not have nasopharyngeal carcinoma) to all those who had negative test results
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 30 Years
- Maximum age
- 62 Years
Show eligibility criteria text
Inclusion Criteria: * residents in Southern China * 30-62 years old * male * a first-degree relative of at least one nasopharyngeal carcinoma patient * no medical record of nasopharyngeal carcinoma * Eastern Cooperative Oncology Group score of 0-2 * be able to comprehend, sign, and date the written informed consent document to participate in the study Exclusion Criteria: * history of nasopharyngeal carcinoma * heavy cardiovascular, liver or kidney disease * on systemic steroid or immunosuppressant treatment or active autoimmune disease
References
Publications (0)
Data not yet available
No reference posted for this study.